Evidence · Randomised trial
Vaginal progesterone prophylaxis for preterm birth (the OPPTIMUM study): a multicentre, randomised, double-blind trial.
- Bronchopulmonary dysplasia
- Intraventricular haemorrhage and white matter injury
- Medical
- Neurodevelopmental follow-up
- Neurology
- Respiratory
This paper is from 2016, more than five years ago. Newer evidence may have been published since.
Summary
The OPPTIMUM study is a UK multicentre, double-blind, placebo-controlled randomised trial of vaginal progesterone prophylaxis in women at high risk of preterm birth. It assessed obstetric, neonatal and childhood outcomes, including a neonatal composite of death, brain injury or bronchopulmonary dysplasia, and cognitive scores at 2 years. Progesterone did not significantly reduce preterm birth or adverse neonatal outcomes and showed no long-term benefit or harm at 2 years. It is relevant to perinatal teams counselling families about preterm birth prevention.
Summary written for NICUlearn. Always read the original.
- Licence:
- Open (Creative Commons)
The full text of this openly licensed paper is available to NICUlearn members, and Neeky can answer questions from it.
Guidelines are shown for education. Follow your unit's own guidance and senior advice.